FDMT vs ANNX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
FDMT · 4D Molecular Therapeutics$10.23 ▼ 4.57%
ANNX · Annexon$3.10 ▼ 9.09%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- FDMT -6.1%
- ANNX -31.3%
Head to head
| Metric | FDMT | ANNX |
|---|---|---|
| Price | $10.23 | $3.10 |
| Change today | ▼ 4.57% | ▼ 9.09% |
| Market cap | $576.76M | $591.37M |
| Return, 3 months | -33.5% | -38.7% |
| Return, year to date | +36.4% | -38.2% |
| Return, 1 year | -5.6% | -27.4% |
| P/E (TTM) | – | – |
| P/B | 1.7 | 4.1 |
| P/E percentile vs own 5y | 42nd | 28th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +4,505.6% | – |
| Net profit growth (YoY) | -37.2% | +6.7% |
| Gross margin | – | – |
| Operating margin | -226.0% | – |
| Net margin | -208.6% | – |
| Return on equity | -56.7% | -129.6% |
| Analyst target vs. price | +183.5% | +545.2% |
| Analyst buy share | 86% | 100% |
| RSI (14) | 37 | 30 |
| 30-day volatility | 85.0% | 81.2% |
| Max drawdown, 1 year | -39.0% | -55.5% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ANNX is the largest of the group by market value.
- FDMT has returned the most over the past year.
- ANNX has been the calmest stock over the last 30 days.